𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease

✍ Scribed by Monty A. Silverdale; S.L. Nicholson; A.R. Crossman; J.M. Brotchie

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
87 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Overactive AMPA receptor‐mediated transmission may be involved in the pathogenesis of levodopa‐induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor‐mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP‐lesioned marmoset model of Parkinson's disease and levodopa‐induced dyskinesia. Topiramate significantly reduced levodopa‐induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa‐induced dyskinesia in patients with Parkinson's disease. © 2004 Movement Disorder Society

📜 SIMILAR VOLUMES

Stimulation of cannabinoid receptors red
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease
✍ Susan H. Fox; Brian Henry; Michael Hill; Alan Crossman; Jonathan Brotchie 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB 👁 1 views

Long-term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa-induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation

The selective mu-opioid receptor antagon
The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease
✍ James B. Koprich; Susan H. Fox; Tom H. Johnston; Allan Goodman; Bertrand Le Bour 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB

## Abstract In Parkinson's disease (PD), dyskinesia develops following long‐term treatment with 3,4‐dihydroxyphenylalanine (L‐dopa). Given the prominent role of the opioid system in basal ganglia function, nonselective opioid receptor antagonists have been tested for antidyskinetic efficacy in the

Fipamezole (JP-1730) is a potent α2 adre
Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
✍ Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurs 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Previous studies in the MPTP-lesioned primate model of Parkinson's disease have demonstrated that alpha(2) adrenergic receptor antagonists such as idazoxan, rauwolscine, and yohimbine can alleviate L-dopa-induced dyskinesia and, in the case of idazoxan, enhance the duration of anti-parkinsonian acti

Pharmacological characterization of psyc
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease
✍ Naomi P. Visanji; Jordi Gomez-Ramirez; Tom H. Johnston; Donna Pires; Valerie Voo 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

## Abstract Investigation of the pathophysiology of psychosis in Parkinson's disease (PD), as well as the assessment of potential novel therapeutics, has been limited by the lack of a well‐validated animal model. MPTP‐lesioned primates exhibit abnormal behaviors that are distinct from dyskinesia an